MicroVAX begin Phase I clinical trials for the exclusive platform of vaccine against cancer

MicroVAX begin Phase I clinical trials for the exclusive platform of vaccine against cancer -

MicroVAX, LLC, a biotechnology company based in Manassas, Virginia announced today the start of a phase I trial for its platform sole and exclusive vaccine that under the provisions of an entry FDA IND patients with breast, prostate, colon, ovarian and lung cancer, who have relapsed after initial salvage therapy.

The trial is sponsored by the Singapore Clinical Research Institute (SCRI), and led by Dr Toh Han Chong, Senior Advisor and Deputy Director of the National Cancer Centre Singapore (NCCS). "Our main objective is to evaluate the safety and benefits of this unique vaccine, designed to target a protein common to most of the more common cancers such as colon cancer, breast cancer and cancer of the ovary, and to provide specific additional boost to the immune system against cancer at the same time. We will also evaluate how powerful this vaccine can stimulate a significant immune response against cancer. " When fully implemented, the MicroVAX vaccine is designed to both destroy pre-existing cancerous tumors and prevent cancer.

NCCS also obtained a research grant to SGD $ 800,000 National Medical Research Council, Singapore to support the evaluation of the immune response induced by vaccination of the subjects of the clinical trial. Jake Frank, managing member of MicroVAX said: "MicroVAX is pleased to be in partnership with Dr Toh Han Chong and his world-class team of clinical immunologists at the National Cancer Center of Singapore Cancer and Research Institute clinical Singapore on the initial clinical test sound vaccine against cancer. "

the vaccine against the MicroVAX cancer

consists of the attachment of the target protein, MUC-1 expressed on the surface of the aforementioned cancers, the immune powerful CD40L stimulation molecule. This new combination aims to further the power of the full body's immune system to attack the protein of cancer of the surface, MUC1, killing the cancer cells themselves.

Pre-clinical testing, the results were reported in the Journal of Immunology, showed that MUC-1 vaccine / CD40L can overcome immune nonresponse states (anergy), inducing an immune memory response and induce a complete withdrawal of existing cancers that are progressing. The concept of vaccine platform was launched at Yale University and was later supported by grants from the Breast Cancer Research Foundation, the Department of Defense, and the Sidney Kimmel Foundation for Cancer Research .

In addition to the implementation of the TAA / ecdCD40L vaccine platform for multiple types of cancer, MicroVAX studied vaccine platform for application to several infectious diseases. "This trial highlights the strong partnership between an academic research organization as SCRI with a biotechnology company and MicroVAX as a prestigious institution of health care as NCCS in the conduct new clinical trials in Singapore. It is also the first time SCRI launches in sponsoring clinical trials to support the clinical trial community in Singapore, "said Dr Teoh Yee Leong, CEO, SCRI.